Are pharma stocks attractive now? BNP Paribas recommends these shares to buy

By:
On:
In: Business
With: 0 Comments

Brokerage BNP Paribas thinks sector valuations look reasonable with FY25E EV/EBITDA averaging 12x for Pharma firms, 18x for Hospital firms and 21x for Diagnostics firms. Its detailed valuation workings for Diagnostics companies show that valuations are attractive now. “We believe the Indian Healthcare is on a long-term structural growth path.Read More →